Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 2/20 | 0.33 |
| ▸ | AMY2A | P04746 | 1/20 | 0.32 |
| ▸ | OGA | O60502 | 1/20 | 0.32 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.31 |
| ▸ | PYGB | P11216 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13864486 | 1.00 | LGALS8 (0.33) | LGALS8AMY2AOGAAMY1APYGB | |
| SCHEMBL17058711 | 1.00 | LGALS8 (0.33) | LGALS8AMY2AOGAAMY1APYGB | |
| SCHEMBL23378918 | 1.00 | LGALS8 (0.33) | LGALS8AMY2AOGAAMY1APYGB | |
| SCHEMBL24709744 | 1.00 | LGALS8 (0.33) | LGALS8AMY2AOGAAMY1APYGB | |
| SCHEMBL23188294 | 0.90 | LGALS8 (0.31) | LGALS8AMY2AOGA | |
| SCHEMBL3903836 | 0.85 | LGALS8 (0.37) | LGALS8AMY2AOGAPYGB | |
| SCHEMBL13205044 | 0.85 | AMY1A (0.38) | LGALS8AMY2AOGAAMY1APYGB | |
| SCHEMBL20845380 | 0.83 | L3MBTL1 (0.31) | — | |
| SCHEMBL26216217 | 0.83 | LGALS8 (0.31) | LGALS8 | |
| SCHEMBL12141264 | 0.83 | LGALS8 (0.45) | LGALS8OGAPYGB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220396791-A1 | RNAi Agents for Inhibiting Expression of Receptor for Advanced Glycation End-products, Compositions Thereof, and Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2022-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220396791-A1 | RNAi Agents for Inhibiting Expression of Receptor for Advanced Glycation End-products, Compositions Thereof, and Methods of Use | AGER, ASGR1, TLR3 | LGALS8 57/4885AMY2A 1804/4885OGA 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.